13 Result(s)

Article

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs subtypes include two basal-like (...

Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen… in Nature Communications (2021)

Article

Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

p53 is mutated in over half of human cancers. In addition to losing wild-type (WT) tumor-suppressive function, mutant p53 proteins are proposed to acquire gain-of-function (GOF) activity, leading to novel onco...

Lindsay N. Redman-Rivera, Timothy M. Shaver, Hailing **… in Nature Communications (2021)

Article

Tissue-specific expression of p73 and p63 isoforms in human tissues

p73 and p63 are members of the p53 family that exhibit overlap** and distinct functions in development and homeostasis. The evaluation of p73 and p63 isoform expression across human tissue can provide greate...

Clayton B. Marshall, J. Scott Beeler, Brian D. Lehmann… in Cell Death & Disease (2021)

Article

Comparison of triple-negative breast cancer molecular subty** using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue

Triple negative breast cancer (TNBC) is a heterogeneous disease that lacks unifying molecular alterations that can guide therapy decisions. We previously identified distinct molecular subtypes of TNBC (TNBCtyp...

Bojana Jovanović, Quanhu Sheng, Robert S. Seitz, Kasey D. Lawrence… in BMC Cancer (2017)

Article

Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients

Brian Z. Ring, David R. Hout, Stephan W. Morris, Kasey Lawrence… in BMC Cancer (2016)

Article

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients

Recently, a gene expression algorithm, TNBCtype, was developed that can divide triple-negative breast cancer (TNBC) into molecularly-defined subtypes. The algorithm has potential to provide predictive value fo...

Brian Z. Ring, David R. Hout, Stephan W. Morris, Kasey Lawrence… in BMC Cancer (2016)

Article

Detection of internal exon deletion with exon Del

Exome sequencing allows researchers to study the human genome in unprecedented detail. Among the many types of variants detectable through exome sequencing, one of the most over looked types of mutation is int...

Yan Guo, Shilin Zhao, Brian D Lehmann, Quanhu Sheng, Timothy M Shaver… in BMC Bioinformatics (2014)

Article

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we identified a TNBC subtype that has a luminal ...

Brian D Lehmann, Joshua A Bauer, Johanna M Schafer… in Breast Cancer Research (2014)

Article

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer

There is a major need to better understand the molecular basis of triple negative breast cancer (TNBC) in order to develop effective therapeutic strategies. Using gene expression data from 587 TNBC patients we...

Bojana Jovanović, J Scott Beeler, Michael W Pickup, Anna Chytil… in Breast Cancer Research (2014)

Article

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Despite improved detection and reduction of breast cancer-related deaths over the recent decade, breast cancer remains the second leading cause of cancer death for women in the US, with 39,510 women expected t...

Melissa D Landis, Brian D Lehmann, Jennifer A Pietenpol… in Breast Cancer Research (2013)

Article

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells

Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast cancer. However, only a small portion of patients have a complete response to paclitaxel-based chemothe...

Joshua A Bauer, Fei Ye, Clayton B Marshall, Brian D Lehmann… in Breast Cancer Research (2010)